Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis.
Atherosclerosis is a chronic inflammatory disease of the vasculature that causes significant morbidity and mortality from myocardial infarction, stroke, peripheral vascular disease, and heart failure. Landmark clinical trials revealed that mineralocorticoid receptor (MR) antagonists improve outcomes...
Main Authors: | Mary Elizabeth Moss, Iris Z Jaffe |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-09-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fendo.2015.00153/full |
Similar Items
-
Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01) -
No Significant Role for Smooth Muscle Cell Mineralocorticoid Receptors in Atherosclerosis in the Apolipoprotein-E Knockout Mouse Model
by: M. Elizabeth Moss, et al.
Published: (2018-07-01) -
Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01) -
Les cibles moléculaires du récepteur minéralocorticoïde dans le coeur
by: Gravez, Basile
Published: (2015) -
Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
by: Luo Shi, et al.
Published: (2019-11-01)